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Abstract
Background: Common polymorphisms in the promoter of the APOC3 gene have been associated with
hypertriglyceridemia and may impact on phenotypic expression of the metabolic syndrome (MetS). The
rs7566605 marker, located near the INSIG2 gene, has been found to be associated with obesity, making it also a
potential genetic determinant for MetS. The objective of this study is to examine the APOC3 -455T>C and the
INSIG2 rs7566605 polymorphisms as potential genetic determinants for MetS in a multi-ethnic sample.
Methods: Subjects were genotyped for both the APOC3 -455T>C and INSIG2 rs7566605 polymorphisms, and
classified for the presence or absence of MetS (NCEP ATP III and IDF definitions). The total study population
included 2675 subjects (≥18 years of age) from six different geographical ancestries.
Results: For the overall study population, the prevalence of MetS was 22.6% (NCEP ATP III definition). Carriers
of ≥1 copy of APOC3 -455C were more likely to have MetS (NCEP ATP III definition) than noncarriers (carrier
odds ratio 1.73, 95% CI 1.40 to 2.14, adjusting for age and study group). The basis of the association was related
not only to a higher proportion of -455C carriers meeting the triglyceride and high-density lipoprotein cholesterol
criteria, but also the blood pressure criteria compared with wild-type homozygotes. Plasma apo C-III
concentrations were not associated with APOC3 -455T>C genotype. The INSIG2 rs7566605  polymorphism was
not associated with MetS or measures of obesity.
Conclusion: Meta-analysis of the sample of multiple geographic ancestries indicated that the functional -455T>C
promoter polymorphism in APOC3 was associated with an approximately 2-fold increased risk of MetS, whereas
the INSIG2 rs7566605 polymorphism was not associated with MetS.
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The metabolic syndrome (MetS) is a clinical entity charac-
terized by abdominal obesity, hypertension, hypertriglyc-
eridemia, low plasma high-density lipoprotein (HDL)
cholesterol and elevated glucose [1,2]. MetS is common,
and will likely become even more pervasive, considering
the poor lifestyle habits prevalent in many societies today.
While the increased prevalence in MetS is primarily
related to an imbalance between caloric intake and
expenditure, genetic factors are also likely to be impor-
tant. Each defining component has been previously asso-
ciated with genetic factors, suggesting that genetic factors
might underlie the overall MetS both independently and
through more complex interactions [3]. While the precise
definition of MetS is controversial, there is no question
that the MetS concept has proven to be valuable clinically
[4,5].
A potential candidate underlying genetic susceptibility to
MetS is apolipoprotein (apo) C-III (APOC3), one of the
most studied genes in lipoprotein metabolism. APOC3
encodes a 79-amino-acid glycoprotein produced mainly
in the liver, which acts as a constituent of triglyceride-rich
lipoprotein particles, inhibiting the action of lipoprotein
lipase and interfering with receptor-mediated lipoprotein
uptake. The common -455T>C single nucleotide poly-
morphism (SNP) of the APOC3 gene, located within an
insulin-response element in the promoter region, has pre-
viously been found to be associated with elevated plasma
triglyceride concentrations in multiple populations [6-8].
Another potential candidate for MetS is the rs7566605
genetic variant, located 10 kb upstream of the insulin-
induced gene 2 (INSIG2) gene, which was shown in a
multi-staged genome-wide association study to be associ-
ated with obesity [9]. INSIG2 encodes a 225-aminoacid
protein which blocks the proteolytic activation of sterol
regulatory element-binding proteins [10], thus having
antilipogenic effects, making it an attractive candidate for
obesity-related traits. However, since the original report of
an association between rs7566605 and BMI, results have
been conflicting, with no association observed in four fol-
low-up studies involving >22,000 subjects [11-14].
Thus, the purpose of this present study is to examine these
two genetic polymorphisms: 1) the APOC3 -455T>C pro-
moter polymorphism and 2) the rs7566605 SNP, located
upstream of INSIG2, as potential genetic candidates for
MetS, defined by both the National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) and
the International Diabetes Federation (IDF) criteria, in a
sample of multiple geographic ancestries.
Methods
Study subjects
The multi-ethnic study included Inuit from Greenland
and Canada (Kivalliq region, Nunavut), Oji-Cree
(Ontario, Canada), and Canadians of South Asian, Chi-
nese and European descent. All subjects for the current
study were collected from one of the following popula-
tion studies: 1) the Greenland Population Study [15]; 2)
the Keewatin Health Assessment Study [16]; 3) the Sandy
Lake Health and Diabetes Project [17]; and 4) the Study of
Health Assessment and Risk in Ethnic Groups [18]. The
details of these studies have been described previously
[15-18]. Signed informed consent was obtained from all
participants and the studies were approved by the relevant
Ethics Review Committee. For the current analysis, the
number of subjects ≥18 years of age with both sufficient
DNA for APOC3 genotype determination and a complete
set of data for MetS diagnosis included 1108 Greenland
Inuit, 200 Canadian Inuit, 509 Oji-Cree, 327 South
Asians, 299 Chinese, and 232 Caucasians; a total of 2675
subjects. There was no exclusion based on diabetes status.
Fewer subjects had DNA available for INSIG2 genotyping.
Physical measurements
Measurements of waist circumference, blood pressure,
fasting analytes, including venous plasma glucose, serum
cholesterol, triglycerides, low-density lipoprotein (LDL)
cholesterol, and HDL cholesterol were performed as
described [15-18]. For a subset of Greenland Inuit, plasma
apo C-III concentrations were determined by a turbidi-
metric immunoassay (Wako Chemicals Inc., Richmond,
VA).
Metabolic syndrome classification
According to the National Cholesterol Education Program
Adult Treatment Panel III (NCEP ATP III) criteria [1],
MetS was identified if a subject had ≥3 of: 1) increased
waist circumference (>102 cm [>40 inches] for men, >88
cm [>35 inches] for women); 2) elevated plasma triglycer-
ides (≥1.69 mmol/L [≥150 mg/dL]); 3) low plasma HDL
cholesterol (<1.04 mmol/L [<40 mg/dL] for men, <1.29
mmol/L [<50 mg/dL] for women); 4) hypertension
(≥130/≥85 mmHg) or current medication; or 5) impaired
fasting glucose (≥6.1 mmol/L [≥110 mg/dL]).
The International Diabetes Federation (IDF) criteria [19]
identifies MetS for subjects with central obesity, according
to ethnic specific guidelines (waist circumference for
Europids ≥94 cm for men, ≥80 cm for women; for South
Asians and Chinese ≥90 cm for men, ≥80 cm for women),
plus any two of: 1) elevated plasma triglycerides (≥1.69
mmol/L [≥150 mg/dL]); 2) low plasma HDL cholesterol
(<1.04 mmol/L [<40 mg/dL] for men, <1.29 mmol/L [<50
mg/dL] for women); 3) hypertension (≥130/≥85 mmHg)
or current medication; or 4) impaired fasting glucosePage 2 of 7
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type 2 diabetes. Since no quantitative thresholds exist yet
for aboriginal populations, these subjects were evaluated
using the Chinese values for waist circumference.
Genotyping of the APOC3 and INSIG2 polymorphisms
Detection of the APOC3 -455T>C promoter polymor-
phism (rs2854116) was carried out using a reported
method [7]. Briefly, the primer set 5'-GTGAGAGCT-
CAGCCCCTGTAA-3' and 5'-TTTCACACTGGAAATT-
TCAGG-3' was used in a gene amplification program with
annealing temperature 60°C to amplify a 194-bp frag-
ment of the APOC3 promoter containing the insulin-
response element. After FokI (New England Biolabs, Mis-
sissauga, ON) digestion, the T allele yielded two frag-
ments with sizes 122 and 72-bp, and the C allele yielded
only a single 194-bp fragment. Electrophoresis in a 2.5%
agarose gel followed by ethidium bromide staining and
ultraviolet illumination allowed detection of the alleles.
Detection of the neighbouring APOC3 -482C>T promoter
polymorphism (rs2854117) was carried out using either a
reported method [7] or by using a custom designed Taq-
Man genotyping assay (Assay ID C_12081482_10;
Applied Biosystems, Foster City, CA). The pairwise linkage
disequilibrium correlation coefficient between the -
455T>C and -482C>T SNPs across all samples was 0.89 (P
< 0.0001), indicating strong linkage disequilibrium. Thus,
for simplicity, considering the strong linkage disequilib-
rium observed, and the known functional impact of the
DNA change, all subsequent analyses in the study were
run using only the -455T>C SNP.
Detection of the rs7566605 SNP, located 10 kb upstream
of the INSIG2 gene, was carried out using a validated Taq-
Man genotyping assay (Assay ID C_29404113_20;
Applied Biosystems, Foster City, CA). SNP genotyping was
performed using an allelic discrimination assay (TaqMan®
SNP Genotyping Assays, Applied Biosystems, Foster City,
CA) using the 7900HT Fast Real-Time PCR System and
genotypes were read using automated software (SDS 2.3,
Applied Biosystems, Foster City, CA). Reactions were run
in 5 µL volumes using an amplification protocol of 95°C
for 10 minutes, followed by 50 cycles of 95°C for 15 sec-
onds, then 60°C for 1.5 minutes. For all experiments, the
genotyping success rate was in excess of 98%. When repli-
cate quality control samples were evaluated, genotypes
showed 100% concordance.
Statistical analysis
SAS version 9.1 (SAS Institute, Cary, NC) was used for all
statistical comparisons with analyses run separately for
men and women. Data are presented as means ± standard
deviation (s.d.) or as percentages for categorical variables.
Differences in demographic and laboratory characteristics
between groups were analyzed using either general linear
or logistic models, adjusting for age. The P-values for
blood pressure, cholesterol, triglycerides, LDL cholesterol,
HDL cholesterol and glucose were also adjusted for BMI,
in addition to age. Logistic regression analysis was also
used to calculate the odds ratio (OR) for the MetS accord-
ing to APOC3 -455T>C and rs7566605 genotype, adjust-
ing for age and study group. The significance of deviations
of observed genotype frequencies from those predicted by
the Hardy-Weinberg equation were evaluated with χ2
tests. The APOC3 -455T>C and rs7566605 G>C genotypes
were included in the analysis as a dichotomous variable,
in both dominant and recessive models. Statistical signif-
icance was taken at nominal P-value < 0.05 for all compar-
isons.
Results
General characteristics of the six population groups
included in the study are presented in Table S1 (see Addi-
tional file 1). Significant differences between the males
and females are shown. Overall MetS prevalence, as
defined by the NCEP ATP III criteria, was 14.9%, 13.5%,
35.4%, 32.4%, 19.4% and 29.3%, for the Greenland
Inuit, Kivalliq Inuit, Oji-Cree, South Asians, Chinese and
Caucasians, respectively. More females had MetS than
males for the Greenland Inuit, Kivalliq Inuit and Oji-Cree
groups (P = 0.017, 0.023, 0.028, respectively), no differ-
ence in MetS prevalence was observed between sex for the
South Asian group, and more males had MetS than
females for the Chinese and Caucasian groups (P = 0.0003
and 0.0078, respectively). The APOC3 -455C allele fre-
quency was 0.41, 0.44, 0.46, 0.54, 0.44 and 0.41, for the
Greenland Inuit, Kivalliq Inuit, Oji-Cree, South Asians,
Chinese, and Caucasians, respectively. The INSIG2
rs7566605 C allele frequency was 0.20, 0.25, 0.22, 0.26,
0.36 and 0.31, for the Greenland Inuit, Kivalliq Inuit, Oji-
Cree, South Asians, Chinese and Caucasians, respectively.
The genotype frequencies did not deviate from the Hardy-
Weinberg predictions (data not shown).
Table S2 (see Additional file 1) shows the demographic
and metabolic characteristics of males and females based
on APOC3 -455T>C genotype, assuming a dominant
model for the C allele. Except for the Caucasian males, a
trend towards elevated triglyceride concentrations was
noted for -455C allele carriers in all groups, with signifi-
cant increases for -455C allele carriers observed in both
the Greenland Inuit females (P < 0.0001) and Oji-Cree
females (P = 0.014), and close to significance for the
Kivalliq Inuit females (P = 0.070). Significantly depressed
HDL cholesterol concentrations were also observed for -
455C allele carriers among Greenland Inuit females (P <
0.0001), Kivalliq Inuit females (P = 0.027), Oji-Cree
females (P = 0.040) and Chinese males (P = 0.013). In
addition, for Greenland Inuit females only, an associationPage 3 of 7
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observed for -455C allele carriers (20.3% vs 11.1%, carrier
OR 2.39, 95% confidence interval [CI] 1.44 to 3.98, P =
0.0008).
Meta-analysis of the 6 multi-ethnic study populations
indicated that APOC3 -455C allele carriers had an
increased risk of MetS (carrier OR 1.73, 95% CI 1.40 to
2.14, P < 0.0001) (Figure 1). Genotype and allele frequen-
cies for the six study populations are shown in Table S3
(see Additional file 1). For females alone, the carrier OR
was 1.92 (95% CI 1.44 to 2.57, P < 0.0001) and for males
alone, the carrier OR was 1.52 (95% CI 1.10 to 2.09, P =
0.010). Repeating the analysis using a recessive model for
the -455C allele indicated that CC homozygotes had an
increased risk of MetS (OR 1.44, 95% CI 1.16 to 1.80, P =
0.0011). For females alone, the OR for CC homozygotes
was 1.39 (95% CI 1.03 to 1.88, P = 0.031) and for males
alone, the OR for CC homozygotes was 1.52 (95% CI 1.09
to 2.11, P = 0.012).
Meta-analysis of the overall sample indicated that signifi-
cantly more APOC3 -455C allele carriers met the MetS cri-
teria for elevated blood pressure (32.9% vs 29.3%, P =
0.039), depressed HDL cholesterol (39.8% vs 30.9%, P =
0.0002), and elevated triglycerides (28.1% vs 18.6%, P <
0.0001) than non-carriers, and tended to meet the criteria
for fasting glucose (22.0% vs 20.0%, P = NS[0.061]), but
not for waist circumference (33.7% vs 33.4%, P =
NS[0.45]). This indicates that the association of the
APOC3 -455C allele with the MetS was related in part to
the lipid components, but also to non-lipid components,
suggesting that this genetic marker may have a broader
relationship with this complex trait.
Table S4 (see Additional file 1) shows the demographic
and metabolic characteristics of males and females based
on the INSIG2 rs7566605 G>C genotype, assuming a
dominant model for the C allele. Significant differences
between C allele carriers and non-carriers were observed
for waist circumference measurements, with C allele carri-
ers having a significantly smaller waist circumference for
Oji-Cree females (P = 0.034), South Asian females (P =
0.013), and Chinese males (P = 0.012). Decreased waist
circumference for C allele carriers among Caucasian
females was close to significance (P = 0.067). No signifi-
cant differences in the prevalence of MetS were observed
for any of the populations depending on rs7566605 gen-
otype.
Overall meta-analysis of the 6 multi-ethnic study popula-
tions indicated no significant association for the INSIG2
rs7566605 SNP with MetS (carrier OR 0.88, 95% CI 0.73
to 1.08, P = NS[0.22]) (Figure 2). Genotype and allele fre-
quencies for the six study populations are shown in Table
S5 (see Additional file 1). For females alone, the carrier
OR was 0.73 (95% CI 0.55 to 0.95, P = 0.021) and for
males alone, the carrier OR was 1.15 (95% CI 0.86 to
1.54, P = NS[0.35]). Repeating the analysis using a reces-
sive model for the rs7566605 C allele indicated no signif-
icant association with MetS (OR 0.93, 95% CI 0.62 to
1.37, P = NS[0.70]). For females alone, the OR for CC
homozygotes was 0.99 (95% CI 0.56 to 1.74, P =
NS[0.97]) and for males alone, the OR for CC homozy-
gotes was 0.87 (95% CI 0.50 to 1.50, P = NS[0.60]).
In the overall sample, carriers of the INSIG2 rs7566605 C
"deleterious" allele were significantly less likely to meet the
MetS criteria for elevated fasting glucose (P = 0.018) and
The age-adjusted odds ratios (ORs) and 95% confidence int rvals (CI) for MetS in carriers of ≥1 copy of INSIG2 rs7566605 CFigure 2
The age-adjusted odds ratios (ORs) and 95% confidence 
intervals (CI) for MetS in carriers of ≥1 copy of INSIG2 
rs7566605 C.
Odds Ratio (95% CI)
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The age-adjusted odds ratios (ORs) and 95% confidence int rvals (CI) for MetS in carriers of ≥1 copy of APOC3 -455CFigure 1
The age-adjusted odds ratios (ORs) and 95% confidence 
intervals (CI) for MetS in carriers of ≥1 copy of APOC3 -
455C.
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riers. These findings directly contradict the initial findings
that INSIG2 rs7566605 C is deleterious for obesity and
related traits.
For comparison, associations between MetS factors and
genotype were repeated, using the IDF definition of MetS.
Once again, APOC3 -455C allele carriers had an increased
risk of MetS (carrier OR 1.47, 95% CI 1.23 to 1.77, P <
0.0001). For females alone, the carrier OR was 1.85 (95%
CI 1.43 to 2.39, P < 0.0001) and for males alone, the car-
rier OR was 1.14 (95% CI 0.87 to 1.48, P = NS[0.35]).
Using a recessive model for the -455C allele indicated that
CC homozygotes had an increased risk of MetS (OR 1.28,
95% CI 1.05 to 1.57, P = 0.017). For females alone, the
OR for CC homozygotes was 1.30 (95% CI 0.98 to 1.72,
P = NS[0.065]) and for males alone, the OR for CC
homozygotes was 1.27 (95% CI 0.95 to 1.71, P =
NS[0.11]).
Upon repeating the meta-analysis for the INSIG2
rs7566605 SNP with the IDF definition of MetS, a modest
significant association – decreased risk – was found (car-
rier OR 0.83, 95% CI 0.69 to 0.99, P = 0.035). For females
alone, the carrier OR was 0.64 (95% CI 0.50 to 0.82, P =
0.0004) and for males alone, the carrier OR was 1.11
(95% CI 0.86 to 1.43, P = NS[0.43]). Using a recessive
model for the rs7566605 C allele indicated no significant
association with MetS (OR 0.75, 95% CI 0.52 to 1.07, P =
NS[0.11]). For females alone, the OR for CC homozygotes
was 0.64 (95% CI 0.37 to 1.13, P = NS[0.13]) and for
males alone, the OR for CC homozygotes was 0.83 (95%
CI 0.51 to 1.35, P = NS[0.45]).
Plasma apo C-III concentrations were measured in a sub-
set of 630 Greenland Inuit and analyzed according to
APOC3 -455T>C genotype (Table S6, see Additional file
1). No significant differences in apoC-III concentration
were observed based on genotype. ApoC-III concentra-
tions for APOC3 -455C carriers vs non-carriers were 3.63
± 1.76 mg/dL vs 3.60 ± 2.26 mg/dL, P = NS(0.93), for the
males, and 4.15 ± 2.15 mg/dL vs 3.96 ± 2.07 mg/dL, P =
NS(0.41), for the females. Plasma apo C-III concentra-
tions were modestly correlated with triglycerides in this
sample (r = 0.25, P < 0.0001).
Discussion
Our study of candidate genes for MetS in a sample from
multiple geographical ancestries showed 1) significant
association with the APOC3 gene, with APOC3 -455C
allele carriers having an increased risk of MetS (carrier OR
1.73, 95% CI 1.40 to 2.14; P < 0.0001); 2) this association
was related to higher proportion of subjects with elevated
triglyceride and depressed HDL cholesterol but also with
lower blood pressure; and 3) no systematic associations of
MetS phenotypes with genotypes of the INSIG2
rs7566605 marker; a few associations with INSIG2 in sub-
groups were statistically significant, but these were oppo-
site to previously reported associations with respect to this
disease phenotype.
The common promoter polymorphisms (-455T>C and -
482C>T) of the APOC3 gene have been well established as
bona fide functional variants, described as an example of
insulin resistance at the gene level [20]. Studies on the
transcriptional activity of promoter constructs containing
either the -455C or -482T alleles, which are located within
an insulin-responsive element (-490 to -449), have found
that these variants are unable to respond effectively to
insulin-mediated down-regulation and instead remain
constitutively active [20]. Furthermore, the -455C variant
has been found to have a reduced affinity for specific DNA
binding proteins [20]. Consequently, considering apo C-
III's inhibitory role towards lipoprotein lipase and the cel-
lular uptake of triglyceride-rich lipoprotein particles, over-
expression of apoC-III may promote the development of
hypertriglyceridemia, as has been observed in overexpres-
sion studies in transgenic mice [21], and in human
APOC3 promoter variant association studies [6-8].
Similarly, triglyceride concentrations were observed to be
~20% higher for -455C carriers (P < 0.0001 for Greenland
Inuit, P = 0.014 for Oji-Cree), particularly in females, as
predicted by the known loss of APOC3 transcriptional reg-
ulation associated with this allele. A significant lowering
of HDL cholesterol concentrations was also observed
among the female -455C carriers, suggesting further
downstream disturbances in lipid metabolism, such as
enhanced cholesteryl ester transfer protein activity or
changes in the expression of the major HDL apolipopro-
tein, apoA-I, whose gene lies within the APOA5/A4/C3/A1
gene cluster [22]. Over-expression of apo C-III for carriers
of the -455C variant however was not reflected in elevated
apo C-III plasma concentrations upon examining a
Greenland Inuit subset of the data, indicating that per-
haps its effect may be intracellular or outside plasma.
Conversely, increased concentrations of apo C-III were
observed to be a common feature of the MetS-phenotype
from a study of 563 Italian subjects, despite no associa-
tion at the genetic level, questioning the mechanistic role
of the APOC3 -455T>C genotype and suggesting another
underlying mechanism, such as reduced protein catabolic
rate for apo C-III, independent of increased apo C-III
expression at the level of transcription [23]. Alternatively,
the -455T>C SNP may be in linkage disequilibrium with
another unmeasured genetic variant that was the actual
determinant of the phenotypic association through an
alternative mechanism. Clearly, this is a complex issue
which remains to be clarified. Nonetheless, our data are
consistent with the concept that APOC3 genotype mayPage 5 of 7
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ment of dyslipidemia and progression of MetS, and are in
line with the recent report of a significant association with
MetS in a small multi-ethnic study group [24].
More importantly, an association between the -455T>C
APOC3 promoter polymorphism and MetS was observed
following meta-analysis of the six multi-ethnic groups,
with female carriers of ≥1 copy of APOC3 -455C found to
have a significant ~2-fold increased risk for MetS (carrier
OR 1.92, 95% CI 1.44 to 2.57; P < 0.0001), adjusting for
age and study group, and male carriers having a significant
~1.5-fold increased risk (carrier OR 1.52, 95% CI 1.10 to
2.09; P = 0.010), resulting in an overall increased risk of
~1.7-fold (carrier OR 1.73, 95% CI 1.40 to 2.14; P <
0.0001). Under the IDF definition of MetS, the same
trends were observed. The associations observed for the
APOC3 -455T>C polymorphism with triglycerides and
HDL cholesterol in these populations suggest that the
association with the overall syndrome was mediated at
least in part through association with some intermediate
quantitative traits that are used in the definition of the
syndrome. Indeed, in examining the relationship between
the prevalence of each particular component of MetS and
APOC3 -455T>C genotype, significant associations were
found for the individual HDL cholesterol and triglyceride
components (P = 0.0002 and <0.0001, respectively).
Interestingly, a significant association was also found for
the blood pressure component (P = 0.039) and fasting
blood glucose was close to significance (P = 0.061). These
findings suggest that the association of APOC3 genotype
with MetS is related to associations with the two plasma
lipoproteins and with additional non-lipoprotein compo-
nents. Caucasian females did not follow the trend towards
increased risk of MetS for -455C allele carriers suggesting
that there may be gender-specific genetic factors associ-
ated with MetS which underlie the observed gender differ-
ences in MetS definition and prevalence, as observed
previously [25,26].
Our study also examined the rs7566605 genetic variant,
located 10 kb upstream of the INSIG2 gene, which was
recently shown in a multi-staged genome-wide associa-
tion study to be associated with obesity [9]. No associa-
tion was observed for the rs7566605 marker with BMI,
making this the fifth study [11-14] that fails to replicate
the original association [9]. If anything, significant find-
ings were in the opposite direction compared to the orig-
inal publication, with waist circumference measurements
significantly lower for carriers of the rare rs7566605 C
allele in three of the groups studied. Also, no significant
association was found for this variant with MetS, in indi-
vidual populations, or in the combined meta-analysis
(carrier OR 0.88, 95% CI 0.73 to 1.08, P = NS[0.22]). Fur-
thermore, upon repeating the meta-analysis with the IDF
definition of MetS, a modest but significant decreased risk
was found overall for INSIG2 rs7566605 C allele carriers
(carrier OR 0.83, 95% CI 0.69 to 0.99, P = 0.035), contrary
to the expected direction of risk. These negative results
again are a cautionary reminder of the great risk of false
positive results in genome-wide association studies and
stress the importance of replication and the use of func-
tional markers [27].
Conclusion
In summary, we report an association between MetS and
a common promoter variant in APOC3. This association
might be due to a direct effect of the genetic variation or
to linkage disequilibrium with other functional changes.
No association, however, was found for the INSIG2
rs7566605 marker with measures of obesity or with MetS.
Finding a consistency in association between MetS and
APOC3 in a multi-ethnic study group, including popula-
tions which differ considerably in MetS prevalence,
strengthens the probability that the -455T>C APOC3 pro-
moter polymorphism plays a key role in MetS expression.
The findings suggest that factors involved in metabolism
of triglyceride-rich lipoproteins may be important in the
development of MetS and could represent markers for
diagnosis or perhaps sample stratification for interven-
tions.
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